-
Molecular Health and Axxam enter into a strategic partnership to bolster the discovery of innovative targets in drug development
Pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companies Milan, Italy and Heidelberg, Germany – June 4, 2025 – Axxam S.p.A., a premier provider of integrated early discovery services, and Molecular Health GmbH, a leader in artificial intelligence (AI)-driven development solutions, are announcing a strategic collaboration…
-
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
-
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
-
Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
-
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
-
The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
-
Target adverse event profiles for predictive safety in the postmarket setting
-
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development
